CSBio CSBio

X
[{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"VUB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eTheRNA and VUB Expand Strategic Collaboration to Engineer Next Generation mRNA Therapeutics with TetraMix\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"eTheRNA immunotherapies"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Trio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ajinomoto Bio-Pharma"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute Myeloid Leukaemia and Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"Hyloris Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).

            Lead Product(s): PTX-252

            Therapeutic Area: Oncology Product Name: PTX-252

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Pleco Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 16, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Plecoid FDC product is a patented, innovative, clinical-stage candidate drug that combines chelating agents with different characteristics. Previous studies demonstrate that elevated levels of toxic metals are associated with inferior survival in patients with AML.

            Lead Product(s): Plecoid

            Therapeutic Area: Oncology Product Name: Plecoid

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pleco Therapeutics

            Deal Size: $9.8 million Upfront Cash: Undisclosed

            Deal Type: Partnership November 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Clinical and preclinical data have demonstrated clinical safety of TriMix, together with its ability to amplify immune responses in multiple disease indications. Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation.

            Lead Product(s): TetraMix-based Vaccine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: VUB

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services will evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.

            Lead Product(s): TRIObody drug conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Trio Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 30, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY